CA3128711C - Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire - Google Patents

Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire

Info

Publication number
CA3128711C
CA3128711C CA3128711A CA3128711A CA3128711C CA 3128711 C CA3128711 C CA 3128711C CA 3128711 A CA3128711 A CA 3128711A CA 3128711 A CA3128711 A CA 3128711A CA 3128711 C CA3128711 C CA 3128711C
Authority
CA
Canada
Prior art keywords
bakuchiol
composition
inflammatory
extract
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3128711A
Other languages
English (en)
Other versions
CA3128711A1 (fr
Inventor
Mei Feng Hong
Qi Jia
Lidia Alfaro Brownell
Original Assignee
Unigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unigen Inc filed Critical Unigen Inc
Priority to CA3128711A priority Critical patent/CA3128711C/fr
Publication of CA3128711A1 publication Critical patent/CA3128711A1/fr
Application granted granted Critical
Publication of CA3128711C publication Critical patent/CA3128711C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Il est décrit l’utilisation d’une quantité efficace d’une composition pour atténuer, réduire ou traiter l’excès de pigmentation dans une couche profonde de la peau résultant d’une affection dérivée d’un trouble inflammatoire de la peau autre que l’hyperpigmentation post-inflammatoire dérivée de l’acné. La composition comprend du bakuchiol, ou un sel pharmaceutiquement acceptable de celui-ci, au moins un conservateur, et un support pharmaceutiquement acceptable et moins de 500 ppm d’impuretés totales de furanocoumarine.
CA3128711A 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire Active CA3128711C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3128711A CA3128711C (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161438890P 2011-02-02 2011-02-02
US61/438,890 2011-02-02
USPCT/US2011/026594 2011-03-01
PCT/US2011/026594 WO2012105990A1 (fr) 2011-02-02 2011-03-01 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA2826262A CA2826262C (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA3128711A CA3128711C (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2826262A Division CA2826262C (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire

Publications (2)

Publication Number Publication Date
CA3128711A1 CA3128711A1 (fr) 2012-08-09
CA3128711C true CA3128711C (fr) 2026-03-10

Family

ID=46603028

Family Applications (4)

Application Number Title Priority Date Filing Date
CA2826262A Active CA2826262C (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA3128718A Pending CA3128718A1 (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA3128711A Active CA3128711C (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA3128715A Pending CA3128715A1 (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA2826262A Active CA2826262C (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
CA3128718A Pending CA3128718A1 (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3128715A Pending CA3128715A1 (fr) 2011-02-02 2012-02-02 Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire

Country Status (8)

Country Link
KR (5) KR102525516B1 (fr)
CN (2) CN103458882B (fr)
AU (1) AU2012212153B9 (fr)
BR (1) BR112013019798A2 (fr)
CA (4) CA2826262C (fr)
MX (1) MX350719B (fr)
PH (1) PH12013501632A1 (fr)
WO (1) WO2012105990A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10471035B2 (en) 2014-10-20 2019-11-12 Sunny BioDiscovery Compositions and methods for using esters of meroterpenes and of other resveratrol analogues
CN105675741A (zh) * 2015-12-30 2016-06-15 成都九芝堂金鼎药业有限公司 一种测定生发丸中有效成分含量的方法
KR20190116858A (ko) 2018-04-05 2019-10-15 주식회사 엑소코바이오 줄기세포 유래의 엑소좀 및/또는 세포외 소포체를 유효성분으로 포함하는 조성물의 염증후 과색소침착의 예방, 완화, 감소 내지는 제거 용도
KR102610938B1 (ko) 2018-08-31 2023-12-08 (주)아모레퍼시픽 유화입자를 형성하는 나노캡슐 및 이를 포함하는 유화 조성물
KR102887367B1 (ko) * 2020-02-27 2025-11-14 (주)아모레퍼시픽 보습 효과를 갖는 조성물
CN111544317B (zh) * 2020-04-29 2022-01-14 珀莱雅化妆品股份有限公司 一种抗衰老组合物阳离子纳米脂质体及其制备方法与应用
CN114478196B (zh) * 2021-01-27 2023-11-10 江苏巴帝恩生物科技有限公司 一种从春榆根里提取补骨脂酚并纯化的方法及在化妆品中的应用
US20250018312A1 (en) * 2023-07-03 2025-01-16 Anju Majeed Furanocoumarins free bakuchiol compositions and their method of preparation thereof
CN117771298A (zh) * 2023-11-23 2024-03-29 常州大学 一种具有抗黑色素生成活性的组合物及其制备方法
KR102899265B1 (ko) * 2024-03-29 2025-12-10 한국세라믹기술원 항산화 및 항염 활성이 개선된 바쿠치올 나노입자의 제조 방법 및 상기 방법에 의해 제조된 바쿠치올 나노입자의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617473B2 (ja) 1987-06-30 1997-06-04 キヤノン株式会社 情報入力装置
CN101217968B (zh) * 2005-05-09 2014-11-26 尤尼根公司 补骨脂酚的组合物及其制备方法
WO2008140673A1 (fr) * 2007-05-14 2008-11-20 Sytheon Ltd. Compositions de traitement pour la peau et procédés

Also Published As

Publication number Publication date
CA2826262A1 (fr) 2012-08-09
AU2012212153A1 (en) 2013-08-29
CA3128718A1 (fr) 2012-08-09
KR102525516B1 (ko) 2023-04-24
KR20230058727A (ko) 2023-05-03
KR102642352B1 (ko) 2024-02-28
CA3128715A1 (fr) 2012-08-09
HK1215792A1 (zh) 2016-09-15
CN105147533B (zh) 2018-07-31
WO2012105990A1 (fr) 2012-08-09
KR102156731B1 (ko) 2020-09-16
KR101954118B1 (ko) 2019-03-05
CA3128711A1 (fr) 2012-08-09
KR102333655B1 (ko) 2021-12-01
AU2012212153B2 (en) 2017-04-06
MX2013008890A (es) 2013-10-17
BR112013019798A2 (pt) 2017-07-04
KR20210145864A (ko) 2021-12-02
KR20140008364A (ko) 2014-01-21
KR20200108120A (ko) 2020-09-16
KR20190025740A (ko) 2019-03-11
CN103458882B (zh) 2015-08-05
CN105147533A (zh) 2015-12-16
MX350719B (es) 2017-09-14
CA2826262C (fr) 2021-10-26
AU2012212153B9 (en) 2017-05-11
CN103458882A (zh) 2013-12-18
PH12013501632A1 (en) 2019-03-22

Similar Documents

Publication Publication Date Title
US11013699B2 (en) Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
CA3128711C (fr) Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
US11918547B2 (en) Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
US10905654B2 (en) Compositions of bakuchiol and methods of making the same
US8911774B2 (en) Topical composition for anti-aging skin treatment using dual DNA repair mechanism and method of use
KR20250057891A (ko) 피부 치료 방법
EP3305370A1 (fr) Activateur d'autophagie des algues
US20080045594A1 (en) Use of at Least One Conjugated Triene-Containing Fatty Acid for Preparing a Medicine for Treating Inflammation
HK1215792B (zh) 用於治疗炎症後色素沉着过度的补骨脂酚组合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210820

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250124

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250124

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250625

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250625

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251016

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260123

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260123

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260129

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260129

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20260306

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20260310